Functional regulation of p73 and p63: Development and cancer

Trends in Biochemical Sciences

Volumn 28, Issue 12, 2003, Pages 663-670

  Melino, Gerry ^a,b   Lu, Xin ^c   Gasco, Milena ^d   Crook, Tim ^c   Knight, Richard A ^e  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P63; PROTEIN P73;

APOPTOSIS; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; CELL CYCLE; DISEASE PREDISPOSITION; DNA SPLICING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; REVIEW;

EID: 0345059168     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2003.10.004     Document Type: Review

References (73)

1. Kaghad M., et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:1997;809-819.
2. Yang A., et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell. 2:1998;305-316.
3. Yang A., et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 404:2000;99-103.
4. Pozniak C.D., et al. p73 is required for survival and maintenance of CNS neurons. J. Neurosci. 22:2002;9800-9809.
5. Yang A., et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 398:1999;714-718.
6. Mills A.A., et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 398:1999;708-713.
7. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer. 2:2002;594-604.
8. De Laurenzi V., et al. Induction of neuronal differentiation by p73, in a neuroblastoma cell line. J. Biol. Chem. 275:2000;15226-15231.
9. Yang A., et al. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 18:2002;90-95.
10. Melino G., et al. p73: friend or foe in tumorigenesis. Nat. Rev. Cancer. 2:2002;605-615.
11. De Laurenzi V., et al. Two new p73 splice variants, γ and δ, with different transcriptional activity. J. Exp. Med. 188:1998;1763-1768.
12. De Laurenzi V., et al. Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants e and z. Cell Death Differ. 6:1999;389-390.
13. Basu S., et al. Akt phosphorylates the yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol. Cell. 11:2003;11-23.
14. Irwin M., et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 407:2000;645-648.
15. Marin M.C., et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25:2000;47-54.
16. Barrera, F.N. et al. Binding of the C-terminal SAM domain of human p73 to lipid membranes. J. Biol. Chem. (in press).
17. Grob T.J., et al. Human ΔNp73 regulates a dominant negative feedback loop for TA p73 and p53. Cell Death Differ. 8:2001;1213-1223.
18. Waltermann A., et al. Differential regulation of p63 and p73 expression. Oncogene. 22:2003;5686-5693.
19. Casciano I., et al. Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 9:2002;246-251.
20. Zaika A.I., et al. ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196:2002;765-780.
21. Bergamaschi D., et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 3:2003;387-402.
22. Flores E.R., et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 416:2002;560-564.
23. Inoue T., et al. Nuclear import and export signals in control of the p53-related protein p73. J. Biol. Chem. 277:2002;15053-15060.
24. Lee C.W., La Thangue N.B. Promoter specificity and stability control of the p53-related protein p73. Oncogene. 18:1999;4171-4181.
25. Kim E.J., et al. Identification of Daxx interacting with p73, one of the p53 family and its regulation of p53 activity by competitive interaction with PML. Nucleic Acids Res. 31:2003;5356-5367.
26. Kim K.C., et al. Amphiphysin IIb-1, a novel splicing variant of amphiphysin II, regulates p73β function through protein-protein interactions. Oncogene. 20:2001;6689-6699.
27. Vella V., et al. Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function. J. Biol. Chem. 278:2003;25151-25157.
28. Agami R., et al. Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature. 399:1999;809-813.
29. Yuan Z.M., et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 399:1999;814-817.
30. Gong J., et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 399:1999;806-809.
31. Sanchez-Prieto R., et al. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene. 21:2002;974-979.
32. Gaiddon C., et al. Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle dependent manner and negatively regulate p73. J. Biol. Chem. 278:2003;27421-27431.
33. Zacchi P., et al. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature. 419:2002;853-857.
34. Costanzo A., et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell. 9:2002;175-186.
35. Samuels-Lev Y., et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell. 8:2001;781-794.
36. Scharnhorst V., et al. Physical interaction between Wilms tumor 1 and p73 proteins modulates their functions. J. Biol. Chem. 275:2000;10202-10211.
37. Budram-Mahadeo V., et al. The Brn-3a transcription factor inhibits the pro-apoptotic effect of p53 and enhances cell cycle arrest by differentially regulating the activity of the p53 target genes encoding Bax and p21 (CIP1/Waf1). Oncogene. 21:2002;6123-6131.
38. Uramoto H., et al. Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem. J. 371:2003;301-310.
39. Balint E., et al. Mdm2 binds p73α without targeting degradation. Oncogene. 18:1999;3923-3929.
40. Dobbelstein M., et al. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene. 18:1999;2101-2106.
41. Ongkeko W.M., et al. MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr. Biol. 9:1999;829-832.
42. Kadakia M., et al. Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol. 20:2001;321-330.
43. Little N.A., Jochemsen A.G. Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene. 20:2001;4576-4580.
44. Calabro V., et al. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J. Biol. Chem. 277:2002;2674-2681.
45. Stros M., et al. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J. Biol. Chem. 277:2002;7157-7164.
46. Shimodaira H., et al. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc. Natl. Acad. Sci. U. S. A. 100:2003;2420-2425.
47. Uramoto H., et al. p73 interacts with c-Myc to regulate Y-box-binding protein-1 expression. J. Biol. Chem. 277:2002;31694-31702.
48. Watanabe K., et al. Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function. J. Biol. Chem. 277:2002;15113-15123.
49. Ohtsuka T., et al. Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. Oncogene. 22:2003;1678-1687.
50. Zeng S.X., et al. SSRP1 functions as a co-activator of the transcriptional activator p63. EMBO J. 21:2002;5487-5497.
51. Serber Z., et al. A C-terminal inhibitory domain controls the activity of p63 by intramolecular mechanisms. Mol. Cell. Biol. 22:2002;8601-8611.
52. Ghioni P., et al. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol. Cell. Biol. 22:2002;8659-8668.
53. Dohn M., et al. p63α and ΔNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene. 20:2001;3193-3205.
54. Ratovistski E., et al. p53 associates with and targets ΔNp63 into a protein degradation pathway. Proc. Natl. Acad. Sci. U. S. A. 98:2001;1817-1822.
55. Patturajan M., et al. ΔNp63 induces β-catenin nuclear accumulation and signalling. Cancer Cell. 1:2002;369-379.
56. Wu G., et al. ΔNp63α and TAp63α regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res. 63:2003;2351-2357.
57. Stevens C., La Thangue N.B. E2F and cell cycle control: a double edged sword. Arch. Biochem. Biophys. 412:2003;157-169.
58. Pediconi N., et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat. Cell Biol. 5:2003;552-558.
59. Fulco, M. et al. p73 is regulated by phosphorylation at the G2/M transition. J. Biol. Chem. (in press).
60. Putzer B.M., et al. Increased ΔN-p73 expression in tumours by upregulation of the E2F1-regulated, TA-promoter-derived ΔN′-p73 transcript. Cell Death Differ. 10:2003;612-614.
61. Narita M., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 113:2003;703-716.
62. Alexander K., et al. pRb inactivation in senescent cells leads to an E2F-dependent apoptosis requiring p73. Mol. Cancer Res. 1:2003;716-728.
63. Fang L., et al. Comparative analysis of p73 and p53 regulation and effector functions. J. Cell Biol. 147:1999;823-830.
64. Jung M.S., et al. p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor. Oncogene. 20:2001;5818-5825.
65. Ozaki T., et al. Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB. Oncogene. 22:2003;3231-3242.
66. Irwin M.S., et al. Chemosensitivity linked to p73 function. Cancer Cell. 3:2003;403-410.
67. Zaika A., et al. Oncogenes induce and activate endogenous p73 protein. J. Biol. Chem. 276:2001;11310-11316.
68. Brooks L.A., et al. E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia. Br. J. Cancer. 86:2002;263-268.
69. Zaika A.I., et al. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res. 59:1999;3257-3263.
70. Di Como C.J., et al. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19:1999;1438-1449.
71. Langerod A., et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol. Biomarkers Prev. 11:2002;1684-1688.
72. van Bokhoven H., McKeon F. Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. Trends Mol. Med. 8:2002;133-139.
73. Whitman M., McKeon F. p53 and TGF-β in development: prelude to tumor suppression? Cell. 113:2003;275-280.